AAAAAA
Results:
1-14
|
Results: 14
Authors:
Ylisirnio, S
Hoyhtya, M
Makitaro, R
Paakko, P
Risteli, J
Kinnula, VL
Turpeenniemi-Hujanen, T
Jukkola, A
Citation: S. Ylisirnio et al., Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer, CLIN CANC R, 7(6), 2001, pp. 1633-1637
Authors:
Kuittinen, O
Ruokolainen, H
Turpeenniemi-Hujanen, T
Citation: O. Kuittinen et al., Amifostine does not protect malignant lymphoma cell lines from the cytotoxic effects of various chemotherapeutics in vitro, LEUK LYMPH, 42(3), 2001, pp. 507-510
Authors:
Koskinen, SOA
Hoyhtya, M
Turpeenniemi-Hujanen, T
Martikkala, V
Makinen, TT
Oksa, J
Rintamaki, H
Lofberg, M
Somer, H
Takala, TES
Citation: Soa. Koskinen et al., Serum concentrations of collagen degrading enzymes and their inhibitors after downhill running, SC J MED SC, 11(1), 2001, pp. 9-15
Authors:
Lundin, J
Lundin, M
Holli, K
Kataja, V
Elomaa, L
Pylkkanen, L
Turpeenniemi-Hujanen, T
Joensuu, H
Citation: J. Lundin et al., Omission of histologic grading from clinical decision making may result inoveruse of adjuvant therapies in breast cancer: Results from a nationwide study, J CL ONCOL, 19(1), 2001, pp. 28-36
Authors:
Talvensaari-Mattila, A
Paakko, P
Blanco-Sequeiros, G
Turpeenniemi-Hujanen, T
Citation: A. Talvensaari-mattila et al., Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy, BREAST CANC, 65(1), 2001, pp. 55-61
Authors:
Kuittinen, O
Savolainen, ER
Koistinen, P
Mottonen, M
Turpeenniemi-Hujanen, T
Citation: O. Kuittinen et al., MMP-2 and MMP-9 expression in adult and childhood acute lymphatic leukemia(ALL), LEUK RES, 25(2), 2001, pp. 125-131
Authors:
Ylisirnio, S
Hoyhtya, M
Turpeenniemi-Hujanen, T
Citation: S. Ylisirnio et al., Serum matrix metalloproteinases-2,-9 and tissue inhibitors of metalloproteinases-1,-2 in lung cancer - TIMP-1 as a prognostic marker, ANTICANC R, 20(2B), 2000, pp. 1311-1316
Authors:
Jaalinoja, J
Herva, R
Korpela, M
Hoyhtya, M
Turpeenniemi-Hujanen, T
Citation: J. Jaalinoja et al., Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms, J NEURO-ONC, 46(1), 2000, pp. 81-90
Authors:
Ylisirnio, S
Sassi, ML
Risteli, J
Turpeenniemi-Hujanen, T
Jukkola, A
Citation: S. Ylisirnio et al., Serum type I collagen degradation markers, ICTP and CrossLaps, are factorsfor poor survival in lung cancer, ANTICANC R, 19(6C), 1999, pp. 5577-5581
Authors:
Kuittinen, O
Savolainen, ER
Koistinen, P
Turpeenniemi-Hujanen, T
Citation: O. Kuittinen et al., Gelatinase A and B (MMP-2, MMP-9) in leukaemia MMP-2 may indicate a good prognosis in AML, ANTICANC R, 19(5C), 1999, pp. 4395-4400
Authors:
Talvensaari-Mattila, A
Paakko, P
Turpeenniemi-Hujanen, T
Citation: A. Talvensaari-mattila et al., MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma, BREAST CANC, 58(3), 1999, pp. 287-293
Authors:
Westerlund, A
Apaja-Sarkkinen, M
Hoyhtya, M
Puistola, U
Turpeenniemi-Hujanen, T
Citation: A. Westerlund et al., Gelatinase A-immunoreactive protein in ovarian lesions - Prognostic value in epithelial ovarian cancer, GYNECOL ONC, 75(1), 1999, pp. 91-98
Authors:
Talvensaari-Mattila, A
Apaja-Sarkkinen, M
Hoyhtya, M
Westerlund, A
Puistola, U
Turpeenniemi-Hujanen, T
Citation: A. Talvensaari-mattila et al., Matrix metalloproteinase 2 immunoreactive protein appears early in cervical epithelial dedifferentiation, GYNECOL ONC, 72(3), 1999, pp. 306-311
Authors:
Vaisanen, A
Kallioinen, M
von Dickhoff, K
Laatikainen, L
Hoyhtya, M
Turpeenniemi-Hujanen, T
Citation: A. Vaisanen et al., Matrix metalloproteinase-2 (MMP-2) immunoreactive protein - A new prognostic marker in uveal melanoma?, J PATHOLOGY, 188(1), 1999, pp. 56-62
Risultati:
1-14
|